These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20513856)

  • 21. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol.
    Potkin SG; Weiden PJ; Loebel AD; Warrington LE; Watsky EJ; Siu CO
    Int J Neuropsychopharmacol; 2009 Oct; 12(9):1233-48. PubMed ID: 19419595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection.
    Lasser RA; Bossie CA; Gharabawi GM; Kane JM
    Schizophr Res; 2005 Sep; 77(2-3):215-27. PubMed ID: 15908183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes.
    Dunayevich E; Sethuraman G; Enerson M; Taylor CC; Lin D
    Schizophr Res; 2006 Sep; 86(1-3):300-8. PubMed ID: 16860974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trajectories and antecedents of treatment response over time in early-episode psychosis.
    Levine SZ; Rabinowitz J
    Schizophr Bull; 2010 May; 36(3):624-32. PubMed ID: 18849294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Symptomatic remission and cognitive impairment in first-episode schizophrenia: a prospective 3-year follow-up study.
    Chang WC; Ming Hui CL; Yan Wong GH; Wa Chan SK; Ming Lee EH; Hai Chen EY
    J Clin Psychiatry; 2013 Nov; 74(11):e1046-53. PubMed ID: 24330905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
    Harvey PD; Rabinowitz J; Eerdekens M; Davidson M
    Am J Psychiatry; 2005 Oct; 162(10):1888-95. PubMed ID: 16199835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia.
    de Haan L; Nimwegen Lv; Amelsvoort Tv; Dingemans P; Linszen D
    Pharmacopsychiatry; 2008 Jul; 41(4):125-8. PubMed ID: 18651339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?
    Schennach-Wolff R; Jäger M; Obermeier M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Kühn KU; Lemke MR; Rüther E; Klingberg S; Gastpar M; Seemüller F; Möller HJ; Riedel M
    World J Biol Psychiatry; 2010 Aug; 11(5):729-38. PubMed ID: 20380620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.
    Walther S; Moggi F; Horn H; Moskvitin K; Abderhalden C; Maier N; Strik W; Müller TJ
    J Clin Psychopharmacol; 2014 Feb; 34(1):124-8. PubMed ID: 24346752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis.
    Pelayo-Terán JM; Diaz FJ; Pérez-Iglesias R; Suárez-Pinilla P; Tabarés-Seisdedos R; de León J; Crespo-Facorro B
    Psychol Med; 2014 Jan; 44(1):37-50. PubMed ID: 23461899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The advantage of using 3-week data to predict response to aripiprazole at week 6 in first-episode psychosis.
    Park JI; Cho DH; Hahn SW; Jeong B; Kim JH; Kim SW; Koo MS; Lee SH; Lee SJ; Lee YH; Park JI; Rho SH; Chung YC
    Int Clin Psychopharmacol; 2014 Mar; 29(2):77-85. PubMed ID: 23970176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidone.
    Kemp DE; Johnson E; Wang WV; Tohen M; Calabrese JR
    J Clin Psychiatry; 2011 Sep; 72(9):1236-41. PubMed ID: 21457677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Criteria for symptom remission revisited: a study of patients affected by schizophrenia and schizoaffective disorders.
    Pinna F; Tusconi M; Bosia M; Cavallaro R; Carpiniello B;
    BMC Psychiatry; 2013 Sep; 13():235. PubMed ID: 24294839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recommended haloperidol and risperidone doses in first-episode psychosis.
    McGorry PD
    J Clin Psychiatry; 1999 Nov; 60(11):794-5. PubMed ID: 10584773
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
    Citrome L; Volavka J; Czobor P; Sheitman B; Lindenmayer JP; McEvoy J; Cooper TB; Chakos M; Lieberman JA
    Psychiatr Serv; 2001 Nov; 52(11):1510-4. PubMed ID: 11684748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient-based and clinician-based support for the remission criteria in schizophrenia.
    Docherty JP; Bossie CA; Lachaux B; Bouhours P; Zhu Y; Lasser R; Gharabawi GM
    Int Clin Psychopharmacol; 2007 Jan; 22(1):51-5. PubMed ID: 17159460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes.
    Correll CU; Zhao J; Carson W; Marcus R; McQuade R; Forbes RA; Mankoski R
    J Am Acad Child Adolesc Psychiatry; 2013 Jul; 52(7):689-698.e3. PubMed ID: 23800482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: analyses of ziprasidone clinical study data.
    Masand P; O'Gorman C; Mandel FS
    Schizophr Res; 2011 Mar; 126(1-3):174-83. PubMed ID: 21185155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
    Schooler N; Rabinowitz J; Davidson M; Emsley R; Harvey PD; Kopala L; McGorry PD; Van Hove I; Eerdekens M; Swyzen W; De Smedt G;
    Am J Psychiatry; 2005 May; 162(5):947-53. PubMed ID: 15863797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.